Who should not take a GLP-1 medication?

Contraindications, cautions, and why a clinician saying no is the system working — not a door slammed shut.

Most writing about GLP-1 medications concerns who might benefit. The equally important question — the one a prescription requirement exists to answer — is who should not take them.

Some exclusions are on the FDA labels of the approved products themselves. Semaglutide and tirzepatide products carry a warning against use in people with a personal or family history of medullary thyroid carcinoma or a rare condition called Multiple Endocrine Neoplasia syndrome type 2, and against use in anyone who has had a serious allergic reaction to the medication. These are not judgment calls; they are contraindications.

Other parts of a history call for clinical judgment rather than an automatic answer: a history of pancreatitis or gallbladder disease, significant gastrointestinal conditions, certain eye complications of diabetes, and pregnancy — including planning to become pregnant or breastfeeding. Medications you already take matter too, particularly ones that affect blood sugar. None of these lists are exhaustive, which is precisely the point: they are what a licensed clinician screens for.

This is what the assessment is actually for. It is not an order form with extra steps — it is where your history gets in front of someone licensed to weigh it. A decline, with an explanation and an alternative where one exists, is good care. A service that never says no is not screening anyone.

If you are unsure whether something in your history rules treatment out, the answer is not to omit it. Clinicians work with what you tell them; the more accurate the picture, the better the decision.

This article is educational and is not a substitute for personalized medical advice. Whether any medication is appropriate for you is a decision for a licensed clinician who has reviewed your health history.